Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Tenofovir disoproxil fumarate (TDF) has demonstrated potent antiviral activity against hepatitis B virus (HBV) in clinical trials. Although its efficacy has been demonstrated in Caucasian populations, TDF has not previously been studied in Korean patients who present the predominance of HBV genotype C and of vertical or perinatal transmission. Objective The aim of this study was to evaluate the efficacy of TDF in Korean chronic hepatitis B (CHB) patients in real-life practice, and to determine the clinical variables that contribute to virologic response.Setting Large academic medical center in Korea. Method We retrospectively investigated the efficacy of TDF treatment for more than 6 months in 151 nucleos(t)ide-naïve CHB patients. Main outcome measure The primary endpoint was a virologic response (VR), defined as an HBV DNA level of <12 IU/mL. Secondary endpoints were rates of alanine aminotransaminase (ALT) normalization, hepatitis B e antigen (HBeAg) seroconversion, virologic breakthrough, and safety. Results All patients were the genotype C2. The median duration of TDF treatment was 13 months (range 7–18 months). Ninety-two (61.0 %) patients were HBeAg positive. The mean pre-treatment HBV DNA level was 6.34 ± 1.42 log10 IU/mL. Among the 131 patients with elevated ALT levels at baseline, 128 (97.7 %) patients achieved ALT normalization during TDF treatment. VR was achieved in 97 (64.2 %) patients. The cumulative rates of VR at 6, 9, 12, and 18 months were 47.0, 59.4, 67.9, and 69.3 %, respectively. Among the 92 HBeAg-positive patients, 14 (15.2 %) patients achieved HBeAg seroconversion. In multivariate analysis, absolute HBV DNA levels at baseline (P < 0.001; OR 0.529; 95 % CI 0.560–0.744) and HBeAg positivity (P = 0.015; OR 0.731; 95 % CI 0.615–0.869) were significantly associated with VR. Virologic breakthrough was observed in four patients. These four patients had poor adherence to TDF. Most of the adverse events were mild in severity. No significant changes were observed in serum creatinine and phosphorus levels. Conclusions TDF was effective and well tolerated in Korean genotype C CHB patients in real life practice, consistent with larger registration trials. The absolute HBV DNA levels at baseline and HBeAg positivity were significantly associated with VR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Evans AA, London WT, Gish RG, Cohen C, Block TM. Chronic HBV infection outside treatment guidelines: Is treatment needed? Antivir Ther. 2013;18(2):229–35.

    Article  CAS  PubMed  Google Scholar 

  2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.

    Article  CAS  PubMed  Google Scholar 

  3. Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141(4):1240–8, 8 e1-2.

  4. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–5.

    Article  CAS  PubMed  Google Scholar 

  5. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98–107.

    Article  CAS  PubMed  Google Scholar 

  6. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57(1):399–408.

    Article  CAS  PubMed  Google Scholar 

  7. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–93.

    Article  CAS  PubMed  Google Scholar 

  8. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–75.

    Article  CAS  PubMed  Google Scholar 

  9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.

    Article  PubMed  Google Scholar 

  10. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.

    Article  Google Scholar 

  11. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–55.

    Article  CAS  PubMed  Google Scholar 

  12. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013;58(2):505–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59(2):434–42.

    Article  CAS  PubMed  Google Scholar 

  14. Pan CQ, Hu KQ, Tsai N. Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients. Antivir Ther. 2013;18(7):841–52.

    Article  CAS  PubMed  Google Scholar 

  15. Lampertico P, Soffrendi R, Vigano M, Yurdaydin C, Idilman R, Papatheodoridis GV, et al. Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naïve patients with chronic hepatitis B followed for 3 years in a multicenter European study. Hepatology. 2012;56(S1):389A.

    Google Scholar 

  16. Marcellin P, Zoulim F, Causse X, Hézode C, Larrey D, Pageaux G, et al. High efficacy and safety of tenofovir DF in 441 naïve and NUC-experienced chronic hepatitis B patients: a real life multicenter prospective cohort study. J Hepatol. 2012;56(S2):S210.

    Google Scholar 

  17. Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C, et al. Tenofovir DF for chronic hepatitis B patients in filed practice—results from the GEMINIS German multicenter observational study. J Hepatol. 2012;56(S2):S212–3.

    Google Scholar 

  18. Pan CQ, Trinh H, Yao A, Bae H, Lou L, Chan S, et al. Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. PLoS ONE. 2014;9(3):e89789.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology. 2011;54(2):443–51.

    Article  CAS  PubMed  Google Scholar 

  20. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106(7):1264–71.

    Article  CAS  PubMed  Google Scholar 

  21. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012;57(3):508–14.

    Article  CAS  PubMed  Google Scholar 

  22. Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, et al. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. J Viral Hepat. 2012;19(10):724–31.

    Article  CAS  PubMed  Google Scholar 

  23. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437–44.

    Article  CAS  PubMed  Google Scholar 

  24. Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol. 2009;50(2):289–95.

    Article  CAS  PubMed  Google Scholar 

  25. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48(1):99–108.

    Article  CAS  PubMed  Google Scholar 

  26. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51(2):422–30.

    Article  CAS  PubMed  Google Scholar 

  27. Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17(1):16–22.

    Article  CAS  PubMed  Google Scholar 

  28. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002;36(6):1408–15.

    Article  CAS  PubMed  Google Scholar 

  29. Lin B, Ha NB, Liu A, Trinh HN, Nguyen HA, Nguyen KK, et al. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013;28(5):855–60.

    Article  CAS  PubMed  Google Scholar 

  30. Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Bozbey HU, et al. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013;57(4):1790–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat. 2012;19(6):377–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011;53(6):1854–63.

    Article  PubMed  Google Scholar 

  33. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology. 2012;143(3):619–28 e1.

  34. Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok AS. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat. 2012;19(3):205–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2009-0094050).

Funding

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, 290-3 Jeonha-dong, Dong-gu, Ulsan, 682-714, Republic of Korea

    Jae Hee Kim, Seok Won Jung, Sung Soo Byun, Jung Woo Shin & Neung Hwa Park

  2. Biomedical Research Center, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Republic of Korea

    Bo Ryung Park, Min-Ho Kim, Chang Jae Kim & Neung Hwa Park

Authors
  1. Jae Hee Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seok Won Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sung Soo Byun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jung Woo Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bo Ryung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Min-Ho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chang Jae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Neung Hwa Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neung Hwa Park.

Ethics declarations

Conflicts of interest

None of the authors has any conflict of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, J.H., Jung, S.W., Byun, S.S. et al. Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice. Int J Clin Pharm 37, 1228–1234 (2015). https://doi.org/10.1007/s11096-015-0193-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-015-0193-1

Keywords

Search

Navigation